Innovative Medicine

Patient data from the Phase 2 study of nipocalimab in Sjögren’s disease identify improvements in most core patient-relevant symptoms, with associated improvements in health-related quality of life Positive Phase 2 data support continued development of nipocalimab in systemic lupus erythematosus; Phase 3 study is recruiting

· TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group · These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn’s disease

· New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure · Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups · Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn’s disease with perianal fistula in more than 20 years

· New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn’s disease · 88% of patients achieved 90-day corticosteroid-free clinical remission

· Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA

· New results suggest earlier treatment may increase the likelihood of long-term remission · Study adds to Johnson & Johnson’s overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control

CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on the established efficacy, safety and tolerability profile of CAPLYTA®, further supporting its potential to reach more patients across bipolar I and II disorders

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation